Skip to main content
David Fajgenbaum, MD, Research, Philadelphia, PA

DavidCharlesFajgenbaumMDMBA, MSc

Research Philadelphia, PA

Asst Prof of Medicine, Translational Medicine/Human Genetics, UPenn; Executive Director, Castleman Disease Collaborative Network

Dr. Fajgenbaum is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Fajgenbaum's full profile

Already have an account?

Education & Training

  • Wharton School - University of Pennsylvania
    Wharton School - University of PennsylvaniaMBA, Health Care Management, 2013 - 2015
  • Perelman School of Medicine at the University of Pennsylvania
    Perelman School of Medicine at the University of PennsylvaniaClass of 2013
  • University of Oxford
    University of OxfordM.S., Public Health, 2008
  • Georgetown University
    Georgetown UniversityBS, Human Sciences, 2003 - 2007

Awards, Honors, & Recognition

  • RARE Champion of Hope - Science Gloabl Genes, 2015
  • 30 under 30 in Healthcare Forbes, 2015
  • Young Investigators Draft Awardee Uplifting Athletes, 2018
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Cytokine Storm  
    David Fajgenbaum, MD, The New England Journal of Medicine
  • Predictors of Response to Anti‐IL6 Monoclonal Antibody Therapy (Siltuximab) in Idiopathic Multicentric Castleman Disease: Secondary Analyses of Phase II Clinical Trial...  
    David C Fajgenbaum, Craig Tendler, British Journal of Haematology
  • International, Evidence-Based Consensus Treatment Guidelines for Idiopathic Multicentric Castleman Disease  
    Aaron Goodman, Corey Casper, Sudipto Mukherjee, Peter Voorhees, Angela Dispenzieri, David C Fajgenbaum, Amy Chadburn, Razelle Kurzrock, Raj Jayanthan, Sunita Nasta, Th..., Blood
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • Type I Interferon Response Identified through Phenotypic and Transcriptional Profiling of Circulating Immune Cells during Idiopathic Multicentric Castleman Disease Flare
    David C Fajgenbaum, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Quantitative Changes in Serum Proteins Including CXCL13 Are Early Indicators of Response to Anti-IL6 Therapy in Idiopathic Multicentric Castleman Disease
    David C Fajgenbaum, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Hypercytokine-Producing Cells and Oligoclonal T-Cell Populations in Lymph Nodes from Castleman Disease Patients
    Anna Wiing, Wenzhao Meng, Gerald Wertheim, Dale Frank, Michele Paessler, Megan S. Lim, Eline T. Luning Prak, David C Fajgenbaum, Vinodh Pillai, Blood (ASH Annual Meeting Abstracts), 1/1/2018
  • Join now to see all

Lectures

  • Frontiers in Medicine: Personalized Medicine 
    1/1/2019
  • Overtime: Battling a deadly disease as a physician, researcher, patient, and entrepreneur 
    1/1/2019
  • MOD1 Genetics Case Presentations 
    1/1/2019
  • Join now to see all

Other

  • Unicentric Castleman disease 
    David C. Fajgenbaum, UpToDate
    1/1/2018
  • HHV-8-associated multicentric Castleman disease 
    David C. Fajgenbaum, UpToDate
    1/1/2018
  • HHV-8-negative/idiopathic multicentric Castleman disease 
    David C. Fajgenbaum, UpToDate
    1/1/2018
  • Join now to see all

Authored Content

  • I Was Read My Last Rites as a Third-Year Medical StudentNovember 2019
  • I Was Read My Last Rites as a Third-Year Medical StudentNovember 2019
  • UpToDate - idiopathic multicentric Castleman disease10/17/2018

Press Mentions

  • New Treatment Could Lead to Remission in Deadly Condition
    New Treatment Could Lead to Remission in Deadly ConditionAugust 15th, 2019
  • Penn Researchers Discover Key Mechanism of Cytokine Storm in Castleman Disease
    Penn Researchers Discover Key Mechanism of Cytokine Storm in Castleman DiseaseMay 7th, 2020
  • Philadelphia Scientist with Rare, Fatal Disease Tried an Experimental Treatment on Himself. It Worked
    Philadelphia Scientist with Rare, Fatal Disease Tried an Experimental Treatment on Himself. It WorkedAugust 13th, 2019
  • Join now to see all

Grant Support

  • mTOR as a Central Regulator of iMCD Pathogenesis and Novel Therapeutic TargetNational Institutes of Health - NHLBI2018–2023

Professional Memberships